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The recent progress in understanding the erosion of 
biodegradable polymers and the manufacturing of controlled 
release devices for proteins and peptides is reported. The 
erosion mechanism of poly(anhydrides) was investigated as 
an example of biodegradable polymers and the erosion be-
havior is modeled mathematically. The results provide useful 
information on the microstructure and chemical environment 
inside these polymers during erosion. It is shown how they 
might affect the stability and the release of proteins. 
Concomitantly proteins were processed in controlled release 
devices. Special attention was paid to the stability of the 
biomolecules during the manufacturing of dosage forms. 
Furthermore, the development of a new type of biodegradable 
nanosphere as a future dosage form is shown. 
Progress in the field of biology and biochemistry has led to the discovery 
of numerous bioactive peptides and proteins in the last few decades. Many 
of them, like insulin, as a classical example, are very useful for medical 
therapy. The rapid development of biotechnology and progress in peptide 
and protein chemistry allowed the mass production of many compounds 
and made their broad introduction into medical therapy possible(7). The 
0097-6156/94/0567-0242$10.88/0 
© 1994 American Chemical Society 
use of such biomolecules poses, however, severe problems. Some of these 
compounds have very short half lives in body fluids (under a minute, in 
some cases(2)) and due to degradation in the gastrointestinal tract the ma-
jority of them cannot be administered orally. These limitations motivated 
the development of controlled release dosage forms that improve protein 
and peptide stability as well as prolong drug activity after application. 
Processing these substances into dosage forms is not always easily 
achieved. Many of them have limited chemical and physical stability. 
Common instabilities are irreversible aggregation(J), oxidation(4) or 
conformational changes(5) all of which may affect activity. The prepara-
tion of controlled release devices for such proteins and peptides has, there-
fore, become one of the major challenges in the field of controlled release. 
Controlled release devices have been prepared for various routes of 
administration such as oral, parenteral, nasal, rectal, buccal, vaginal and 
transdermal(6-7). They all control the release of peptides and proteins by a 
few basic principles. Classical systems control release by diffusion 
through a polymer matrix, in which the drug might be dissolved or sus-
pended^). Closely related to diffusion controlled release systems are 
those in which swelling controlled release occurs(9). The swelling of the 
polymer, usually an ionic network, increases the permeability of the ma-
trix and allows drugs to be released by diffusion. Parenterally applied 
dosage forms are the most often used at present as many proteins and pep-
tides are unstable in the gastrointestinal tract resulting in poor bioavail-
ability. The introduction of degradable drug carrier materials brought new 
progress into this field of controlled release research. Biodegradable 
polymers as drug carriers control the release of the drugs through diffusion 
and erosion and have the advantage of dissolving after the application. 
Instead of simple diffusion-controlled release, drug is release by an ero-
sion-controlled mechanism, which provides the advantage of decreasing 
the release rate of the proteins and peptides. The search for new 
biodegradable polymers for controlled release stimulated research in sev-
eral areas, such as polymer synthesis, polymer processing and the formu-
lation of devices. In the area of polymer synthesis, there have been major 
efforts to 'design' polymers for the purpose of controlled release. 
Appropriate examples are poly(ortho esters)(70) and poly (anhydrides) 
(77). In providing the biodegradable polymer raw material for controlled 
release devices for peptides and proteins two fundamental problems arose: 
1. In order to efficiently design a controlled release device from bio-
degradable polymers, the polymer properties and its erosion mech-
anism should be known. 
2. The technology for manufacturing devices ranging from the centimeter 
to the nanometer scale must be developed. The requirements of stabil-
ity for such sensitive compounds as peptides and proteins must, 
thereby, be met. 
The successful design of release systems wil l heavily depend on 
detailed knowledge in both areas. Unfortunately, a unique theory does not 
exist for either set of issues. There is not, for example, a basic theory that 
could predict the erosion of all biodegradable polymers or the stability of 
proteins and peptides from their structural formulas alone. Due to the ex-
panded research in these areas, however, there is progress towards a 
broader understanding of polymeric properties and the development of 
stable protein formulations compatible manufacturing technology. This 
article intends to show some of the progress that has been made in under-
standing the release of peptides and proteins from polymers. The focus 
wil l be on two major areas: 
1. Understanding the erosion mechanism of biodegradable polymers. 
2. Providing some examples to illustrate recent advances in the develop-
ment of controlled release systems. We cover the release of proteins from 
polymers as well as the development of future dosage forms. 
The Erosion of Biodegradable Polymers 
Investigating erosion mechanisms of biodegradable polymers might look 
rather academic and not that beneficial at first glance. The 
microenvironment of a biodegradable polymer during erosion, however, 
provides the medium in which peptides and proteins are embedded and 
from which they have to be released. Factors like pH or the amount of 
dissolved monomers not only influence release rates, but also affect the 
stability of proteins and peptides substantially(7 2) and thus become very 
important parameters for the stability of a controlled release dosage form. 
The design of manufacturing systems for the controlled release of proteins 
and peptides from polymers requires, therefore, a fundamental knowledge 
the erosion mechanism of a biodegradable polymer. 
Diffusion controlled protein release from non-degradable polymers 
is well-understood(73). The release of such compounds from biodegrad-
able polymers in contrast depends heavily on the erosion of the polymer, a 
complex process whose mechanism is not entirely understood. The ero-
sion of biodegradable polymers follows mechanisms specific for a certain 
type of polymer and is influenced by a number of parameters. Most 
important is the chemical degradation of bonds in the polymer chain. The 
rate at which the bonds are cleaved depends on the type of bonds between 
the monomers(74), the diffusivity of water in the polymer(75), and the 
polymer crystallinity(76). The pH of the degradation medium exhibits a 
catalytic effect on the hydrolysis of bonds(77), influences the solubility of 
degradation products, and finally regulates their release. Degradation 
products such as Monomers and oligomers carry functional groups that 
change pH inside cracks and pores in the eroded polymer and these groups 
can have feedback on the erosion process(7S). It can be concluded that the 
polymer erosion is a composite process that can be very complex and is 
specific for each polymer. The erosion mechanisms of poly(lactic-co gly-
colic acid) and poly(ortho esters), for example, follow completely differ-
ent mechanisms(79-20). 
Investigation of Erosion Mechanisms. We were interested in the erosion 
mechanism of a class of related poly(anhydrides) consisting of sebacic 
acid (SA), l,3-bis(p-carboxyphenoxy)propane (CPP) and a fatty acid 
dimer (FAD) monomers which are shown in Figure 1. The techniques that 
were used for these studies may be applied to any class of polymer and the 
results that we obtained provide a clear outline for the important funda-
mental characteristics of polymer erosion. 
The Structure of Polymers. Prior to the investigation of eroded 
polymer discs, the polymers were investigated for their internal structure. 
Figure 2 shows the appearance of various polymers that were taken from 
thin melted polymer films under polarized light. The Maltese Crosses in-
dicate that these polymers are partially crystalline and consist of 
spherulites. The crystallinity of the polymers depends on the copolymer 
composition. In the case of poly(l,3,-bis(p-carboxyphenoxy)propane-co-
sebacic acid) abbreviated p(CPP-SA) changing the content of either 
monomer to a 50:50 composition lowers the crystallinity from more than 
60% to almost 10% (27). Concomitantly, the glass transition temperature 
drops substantially. p(FAD) homopolymer is amorphous(22), so that the 
crystallinity of p(FAD-SA) copolymers depends only on the SA monomer 
content. As shown in Figure 3, increasing the content of F A D monomer 
above 80% results in amorphous polymers. The effect of microstructure 
and crystallinity on erosion is observed in investigating eroded polymer 
discs that were produced from the polymer by melt molding(77). Figure 4 
a shows a scanning electron photograph of a cross section through a disc 
of p(CPP-SA) 20:80 that has been eroded in phosphate buffer pH 7.4 at 
37°C for 3 days. Eroded and non-eroded polymer sharply separated by the 
erosion front are readily distinguishable. Observation of this front with 
time confirms that the erosion of these polymers starts on the surface and 
moves towards the center of the discs which has been referred to as sur-
face erosion(23). Figure 5 shows the kinetics of front movement in p(CPP-
SA) 20:80 and p(CPP-SA) 50:50 as measured from S E M pictures. The 
way erosion affects the polymer can be seen from S E M pictures showing 
the eroded parts of the polymer in more detail. As shown in Figure 4b the 
amorphous parts of the spherulites have been eroded, while the large parts 
of the crystalline skeleton remain in place(24). As erosion progresses, a 
highly porous erosion zone is created. Once the erosion front has reached 
a certain spot in the matrix, the release of drug begins from that point. The 
release of compounds is then determined by the diffusion through pores 
and cracks. 
pH Changes during Erosion. When these polymers erode, they 
release oligomers and monomers that carry carboxylic groups (25). We 
suspected that the pH in the vicinity of the polymer surface or inside the 
cracks and pores of the polymer is not determined by the pH of the buffer 
medium, but instead by the released monomers. To support this hypothe-
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Figure 1. Monomers contained in the investigated poly (anhydrides). 
Figure 2. Polarized light microscopic pictures of poly(anhydride) 
films: a) pSA (250x), b) p-(FAD-SA) 20:80 (400x), c) p-(FAD-SA) 
50:50 (400x). 
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Figure 3. Crystallinity of p(FAD-SA) poly(anhydrides) depending on 
F A D content. 
Figure 4. S E M pictures of cross sections through eroded p(CPP-SA) 
20:80 dies: a) erosion front separating eroded(right) from non-eroded 
(left) polymer, b) eroded polymer. 
sis, we measured the pH on the surface of p(CPP-SA) 20:80 during ero-
sion using confocal microscopy(26). Figure 6 shows the value for the pH 
as a function of the distance from the surface of the polymer matrix disc. 
The pH clearly drops when approaching the surface of the polymer. This 
effect is due to the high concentration of released monomers upon degra-
dation. Keeping in mind the highly porous structure of the eroded zone of 
the polymer it can be hypothesized that the pH inside this network is de-
termined by the monomers and is even lower than the pH at the sur-
face(26). This issue is very important with respect to the stability of pH 
sensitive drugs such as some proteins or peptides. 
Changes in Crystallinity. From the structural changes during ero-
sion, changes in polymer crystallinity could be suspected. They were in-
vestigated by differential scanning calorimetry and x-ray diffraction. In 
the case of the p-SA homopolymer, it was found that the crystalline re-
gions are more resistant towards degradation than the amorphous regions. 
These results agree with the S E M pictures obtained from the degraded part 
of polymer discs. The monomers SA and CPP were found to crystallize to 
relatively high extents in all polymers qualitatively shown by wide-angle 
x-ray diffraction and quantitatively by DSC. Figure 7 shows the calculated 
amount of crystallized monomers in p(CPP-SA) 20:80, as determined by 
D S C according to (26). The presence of crystallized material proves indi-
rectly that the pores of eroded polymer are filled with a saturated solution 
of monomers. F A D monomer is liquid at room temperature and therefore 
not able to crystallize upon release. Due to its low solubility in aqueous 
buffer solution, however, it sticks to the eroding discs as a film. 
The Release of Monomers during Erosion. The release of acidic 
monomers indicates the importance of pH during erosion. A s an example, 
the release profile of SA and CPP monomer during the erosion of p(CPP-
SA) 20:80 is shown in Figure 8. The release profile of SA is similar to the 
release of substances from monolithic devices. The release profile of CPP 
is discontinuous as the release rate increases after SA has completely left 
the eroded polymer matrix. This spontaneous increase can be explained by 
the higher solubility of SA compared to CPP. The dissolved SA, therefore, 
controls the pH inside the pores of the eroded zone limiting, thereby, the 
solubility of CPP. After SA has been completely released, the pH inside 
the pores starts to rise, which increases the solubility of CPP(26). This 
process finally increases the release rate of CPP from the eroded polymer 
matrix. 
Modeling Polymer Erosion. The modeling of polymer erosion is the first 
step towards the theoretical design of controlled release systems with an a 
priori adjusted release rate. The lack of knowledge about erosion, how-
ever, hindered the development of models substantially. The first attempts 
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Figure 6. pH in the degradation medium as a function of distance to 
the surface of a p(CPP-SA) 20:80 polymer disc after 2 days of erosion 
in daily changed 0.1 M phosphate buffer pH 7.4 at 37°C. 
(Reproduced with permission from ref. 26. Copyright 1993 Wiley & 
Sons.) 
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Figure 7. Content of crystallized monomers in a p(CPP-SA) 20:80 
matrix during erosion: o CPP, • SA. 
(Reproduced with permission from ref. 26. Copyright 1993 Wiley & 
Sons.) 
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Figure 8. Release of monomers during the erosion of a p(CPP-SA) 
20:80 polymer matrix disc: o CPP, • SA. 
(Reproduced with permission from ref. 26. Copyright 1993 Wiley & 
Sons.): 
to describe the erosion of biodegradable polymers stem from the descrip-
tion of the dissolution of erodible tablets(27). It was assumed that erosion 
could be described by surface dissolution kinetics. Later, diffusion pro-
cesses were taken into account and modeled as a pseudo-steady state pro-
cess, where erosion was modeled assuming first order kinetics or a con-
stantly moving erosion front(2S-29). Introducing non-steady state analysis, 
erosion was described as a moving front problem with constant veloc-
ity(JO). A l l these models describe erosion in one dimension and do not 
allow descriptions of the microstructural changes upon erosion. Inspired 
by the two-dimensional description of the dissolution of matrix tablets(37-
32), a two-dimensional model able to describe the structural changes of 
our investigated polymers upon erosion was developed. Rather than taking 
individual factors of polymer erosion into account, we combined them by 
regarding the erosion of small parts of polymer matrix as a random 
event(JJ). 
The Basic Concept. A polymer matrix was represented by a two-
dimensional computational grid, in which each grid point represents either 
an amorphous or crystalline part of the polymer matrix. The erosion of 
such a 'polymer pixel' was assumed to depend on two features: the contact 
of the polymer with the degradation medium, and the crystalline or amor-
phous nature of a matrix part which is represented by a pixel. Polymers 
not in contact with water will not erode. Pixels on the surface of the poly-
mer matrix or next to an eroded neighbor have contact to water. The ero-
sion of crystalline matrix parts occurs at a slower rate than amorphous 
parts, a characteristic which was observed in the structural studies(26). 
Besides these fundamental assumptions, a general algorithm must be de-
fined to develop a working model: the matrix must be represented by a 
computational grid divided into individual pixels. A distribution must be 
chosen for crystallites and amorphous parts. After contact with an eroded 
neighbor, each pixel is assigned an individual life expectancy after which 
it is regarded eroded. The life expectancies are distributed according to a 
first order Erlang distribution 34) from which they are chosen randomly. 
To account for the crystalline or amorphous nature, different constants are 
chosen for use in the Erlang distribution. 
The Representation of a Polymer Matrix. To represent a polymer 
matrix prior to erosion, it is sufficient to represent only a cutout of the 
matrix, if the erosion problem is symmetrical. Figure 9 shows such a 
cutout for a cross section through a cylindrical matrix. 
To account for the crystallinity, some of the pixels have to be designated 
to represent crystalline polymer matrix parts. In the easiest case, a random 
distribution of them can be assumed: 
1-X Xij=0 
c(xij)= 1 X xy=l 
0 all other values 
for: 
l ^ i ^ n x , (1) 
X is the crystallinity of the polymer. The status Xjj (1 for crystalline and 0 
for amorphous) of all pixels is assessed from consecutive Bernoulli tri-
a l s ^ ) . c(Xij) is the probability that a pixel at location x=i and y=j on the 
grid represents an amorphous or crystalline part of the matrix. Figure 10a 
shows the theoretical representation of a polymer matrix prior to erosion. 
Dark pixels represent crystalline, whereas white pixels represent amor-
phous parts of the polymer. 
The Simulation of Erosion. After having set up the grid, the ero-
sion algorithm can be applied. A first order Erlang distribution34) was 
used for the calculation of the life expectancy of a pixel after its contact 
with water 
e(t) is the probability that a pixel degrades after a time t. Random variable 
t is the time that elapsed between the first contact with water and the ero-
sion of the pixels. X can be considered as a rate constant and is different 
for amorphous and crystalline pixels. To achieve results independent from 
the grid size, the grid size n has to be taken into account in equation 2: 
Using Monte Carlo sampling techniques( 36), the life expectancy of an in-
dividual pixel can now be calculated from equation 3. Erosion begins at 
the pixels that represent the surface of the polymer matrix. Their lifetime 
is calculated and the pixel with the shortest lifetime is determined. Erosion 
proceeds with the removal of eroded pixels from the grid, now considered 
to represent aqueous pores. They then initiate the erosion process of non-
eroded neighbors, the life expectancies of which are calculated(ii). The 
next pixel is eroded, and so on. As an example, the erosion of the grid 
shown in Figure 10a can be seen in Figure 10b. In contrast to Figure 10a 
dark pixels represent non-eroded polymer and white pixels eroded poly-
mer. The appearance of the cross sections of eroded discs shown in Figure 
4a agrees with the appearance of the lattice during erosion. In both cases, 
the erosion front is clearly visible. 
e(t)= X * e - t 3 ^ (2) 
e n(t)= X+n+e-1*^*11 (3) 
polymer 
matrix 
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Figure 9. Representation of a polymer disc by a computational grid. 
(Reproduced with permission from ref. 33. Copyright 1993 ACS. ) 
Figure 10a. Theoretical representation of a polymer matrix: prior to 
erosion (dark pixels = crystalline areas, white pixels = amorphous areas). 
(Reproduced with permission from ref. 33. Copyright 1993 ACS.) 
t* Xa = 0.042 t* Xa = 0.074 
t*Xa = 0.339 t**a = 0.396 
Figure 10b. Theoretical representation of a polymer matrix: changes during 
erosion (dark pixels = non-degraded areas, white pixels = degraded areas). 
(Reproduced with permission from ref. 33. Copyright 1993 ACS.) 
The Quantitative Evaluation of Experimental Results. The un-
known parameters in this model are the erosion rate constants for amor-
phous and crystalline pixels. Once these parameters are known the model 
becomes a tool to estimate the erosion behavior of polymer matrices and 
to predict when the last portion of drug wil l be released. The computa-
tional grid can, thereby, be fit to any desired shape. 
In order to determine the erosion rate constants, system parameters 
must be defined to develop a model to fit the experimental data. Therefore 
two functions were chosen: 
i n (4) 
f(o = - 2 fid) 
i=0 
i n n (5) 
i=l j=l 
Equation 4 defines the position of the erosion front f(t) at time t as an av-
erage value of the position fj(t) of the foremost eroded pixel in each col-
umn of the grid. Experimentally, the position of the erosion front was de-
termined by S E M . Equation 5 calculates the remaining mass of the matrix 
m(t) at time t, s(xij) being equal to 1 for non-eroded pixels and 0 for 
eroded pixels. Experimentally, the remaining mass was determined by 
weighing dried eroded polymer matrix discs. Using equations 4 and 5, the 
model was fit to experimental data of p(CPP-SA) 20:80 and p(CPP-SA) 
50:50, minimizing the squared distances between experimental points and 
simulated data calculated from equation 4 and 5 (37-38). A s shown in 
Figures 11a and b, the movement of the erosion front is almost linear in 
both polymers. The larger deviation between experimental and predicted 
data for p(CPP-SA) 50:50 (cf. Fig. l i b ) is mainly due to problems in the 
determination of erosion fronts in this polymer by light microscopy. The 
loss of mass after an induction period also follows linear kinetics. From 
the good fit to this parameter it can be assumed that the effect of the error 
in the determination of the erosion front movement has only moderate ef-
fect on the determination of the rate constants. The erosion rate constants 
obtained are shown in Table I. 
As expected from the structural information on eroded polymer matrices, 
the erosion rate constants for crystalline pixels are substantially lower 
Figure 11. Fit of theoretical functions for mass loss and erosion front 
movement to experimental data: a) p(CPP-SA) 20:80, b) p(CPP-SA) 
20:80. 
(Reproduced with permission from ref. 33. Copyright 1993 ACS. ) 
Table I. Erosion rate constants for crystalline and amor 
phous areas in two poly(anhydrides) 
X a [s-1] 
p(CPP-SA) 20:80 7.32*10-7 8.75*10-9 
p(CPP-SA) 50:50 2.7*10-7 3.85*10-11 
Source: Reprinted with permission from ref. 33. Copyright 
1993. 
compared to the rate constants for amorphous pixels. The obtained micro-
constants allow the simulation of erosion of any kind of polymer matrix 
cross section under various boundary conditions. A good example is the 
simulation of erosion of devices partially coated with a water impermeable 
coating. Such devices could be very useful for the modification of release 
profiles for slowing down the overall erosion velocity of a biodegradable 
device. 
The Consequences for the Release of Proteins from Polymers. The ero-
sion of the poly(anhydrides) follows a well defined pattern. A l l polymers 
degrade from the surface of the polymer matrix discs towards their center. 
A moving front sharply separates eroded from non-eroded polymer. It 
could be shown by scanning electron microscopy that crystalline areas of 
the polymers are more resistant to erosion than amorphous areas. Due to 
the spherulitic microstructure of the polymers (cf. Figure 2), erosion cre-
ates highly porous devices consisting of the crystalline skeleton of eroded 
spherulites. Due to the high degradation rates, many oligomers and finally 
monomers are released. Reaching the limit of solubility, these substances 
start to precipitate out of solution, which was observed by wide angle x-
ray diffraction and differential scanning calorimetry. Substantially high 
amounts of monomers were found to be in a crystalline state(26). 
Confocal fluorescence microscopy showed that the pH on the surface of 
the polymers during erosion was lower than in the buffer medium. From 
the presence of crystalline monomers inside the erosion zone, it can be 
concluded that the aqueous phase inside the polymers is saturated with 
monomers. A s SA has the highest solubility of all monomers, this com-
pound determines the pH. From the pKa which is about 4.5 and the solu-
bility which is 0.011M, the theoretical pH minimum is about 3.5(59). Due 
to the diffusion of hydroxide ions from the degradation medium into the 
erosion zone, however, some of the free acids are neutralized, which 
buffers the pH probably around the pKa. Buffer salts like HPO42" are ap-
parently not able to raise the pH inside the porous zones of the eroded 
discs. The major reason is the long diffusion pathway into the disc along 
which they get steadily protonated by dissolved monomers and lose their 
potential to raise pH. The monomer saturated solution inside polymer 
pores with a pH of approximately 4.5 is, therefore, the environment that 
proteins and peptides will be in contact prior to release out of the matrix. 
Once the stability data of such a biomolecule is known, it can readily be 
decided whether these types of polymers wil l make suitable drug carriers. 
The well defined erosion behavior of the investigated polymers allows the 
development of mathematical models that describe changes in polymer 
microstructure during erosion(JJ). Once fit to experimental data, these 
models are a useful tool to predict changes in polymer microstructure. 
They describe important parameters like porosity, loss of weight, eroded 
polymer area and may, therefore, become an important tool to predict the 
release kinetics of proteins and peptides from such polymers in the future. 
Controlled Release Devices for the Delivery of Proteins and Peptides 
from Polymers 
For the delivery of proteins and peptides, non-degradable and 
biodegradable polymers have been used in controlled release. Due to the 
high molecular weight of proteins, direct diffusion through a non-
degradable polymer matrix is not possible(40). By the introduction of a 
network of pores in manufacturing, however, the release of such large 
compounds does occur(47). Another possibility is the creation of hy-
drophilic pathways using swellable polymers, or embedding the com-
pounds into gels. In the case of biodegradable polymers, pores are created 
upon erosion of the polymer matrix enabling the release of proteins from 
the dosage form. A l l of these options have certain advantages and disad-
vantages. Embedding suspended compounds into a non-degradable matrix 
prevents some of the protein from being released(42), or might cause 
some instabilities due to the intense contact with organic solvents(43). 
Their disadvantage with respect to parenteral application, however, is the 
need for removing such systems after therapy. By using gels as a carrier, 
the protein may be released very quickly if not combined with some other 
sort of material(44-45). Degradable polymers change their properties sub-
stantially during erosion, a characteristic which may or may not be bene-
ficial for the stability of proteins and peptides. In general, decisions about 
the suitability of a release device for specific proteins or peptides and ap-
propriate manufacturing technology must be made on a case by case basis. 
In the following section, we provide a number of examples from the 
progress we made in the delivery of proteins from polymers. 
Biodegradable Polymers for Immunization. The idea of using polymers 
as antigen releasing carriers for the stimulation of immune responses 
emerged in the seventies (46). Due to their ease of application and the 
progress in their development, microspheres emerged as a potentially 
efficient carriers to enhance the immune response (47). They have so far 
been used for a number of vaccines (48-50). These microspheres were 
made from polymers based on poly-lactic acid (PLA) and its copolymers 
with glycolic acid (PLGA). For these applications, loading a polymer with 
a high molecular weight protein requires adjusting the desired release rate 
and preventing the protein's loss of activity. 
In an attempt to develop a controlled release system for vaccination 
against tetanus, we investigated the design of microspheres with a desired 
release rate and methods to maintain the imunogenicity of the processed 
tetanus toxoid(57). For the manufacturing of microspheres, the solvent 
evaporation and solvent extraction methods were applied to the double 
emulsion technique. The solvent evaporation method has been used suc-
cessfully for the encapsulation of hydrophilic drugs and peptides(52-5J) 
and was recently applied to the encapsulation of proteins(54). According 
to the protocol, of saline tetanus toxoid solution (3600 Lf/mL) was 
emulsified by vortex mixing in l m L organic solution (methylene chloride 
or ethyl acetate) containing 200 mg of polymer. The emulsion was ho-
mogenized by sonication and dispersed into l m L of a 1% aqueous P V A 
solution by vortex mixing. The final double emulsion was diluted by 
adding it to 100 mL of a 0.3% P V A solution while stirring with a mag-
netic stirrer. The organic solvent was then allowed to evaporate for 3 
hours (solvent evaporation) or extracted by adding 200 m L of 2%(V/V) 
aqueous isopropanol solution (solvent extraction). Both techniques pro-
duced microspheres with a high loading capacity (>80%). Critical points 
in the encapsulation procedure are the protein stability upon contact with 
moisture(55) and organic solvent (43) during the formation of the emul-
sion as well as the subsequent freeze drying. 
Protein stability under the manufacturing conditions was investi-
gated varying three parameters. We varied the type of solvent for the dis-
solution of polymer using methylene chloride and ethyl acetate and inves-
tigated the effect of three different types of stabilizers: Pluronic F68, P E G 
4,600 and sodium glutamate. To mimic the conditions that prevail during 
the manufacturing of microspheres, emulsions were prepared from 100/^L 
aqueous tetanus toxoid solution and dispersed it in l m L of organic sol-
vent. These emulsions were freeze dried and investigated for aggregation 
by HPLC(56). Table II shows the results from this study. 
Table II gives a good survey on the impact of manufacturing conditions on 
the stability of the protein. Sample one shows that moisture alone causes 
Table II. manufacturing conditions and their effect on protein aggre-
gation 
Set of conditions Solvent Stabilizer Aggregation 
(%) 
1 none none 14 
2 none Pluronic F68 0 
3 none PEG 4,600 3.9 
4 none Sodium 
Glutamate 
4.4 
5 Methylene 
chloride 
none 13.11 
6 Methylene 
chloride 
Pluronic F68 9.6 
7 Methylene 
chloride 
P E G 4,600 9 
8 Methylene 
chloride 
Sodium 
Glutamate 
3.4 
9 Ethyl acetate none 5.4 
the protein to aggregate substantially. The impact of even small amounts 
of moisture on the structure of lyophilized proteins can be tremen-
dous(55). The aggregation of the protein in methylene chloride (sample 5) 
is higher than in ethyl acetate (sample 9) which is unfortunately the poorer 
of both solvents for many biodegradable polymers. The use of stabilizers 
like Pluronic F68 might be benefical in preventing some of the proteins 
and peptides from aggregating or from adsorbing to hydrophobic surfaces 
i.e. polymer forming the microspheres. This has been reported for a num-
ber of surfactants(57). 
The goal for the release of tetanus toxoid from microspheres was 
continuous release over a period of weeks. For that purpose two types of 
polymers were used: L - P L A and D,L-PLGA1:1 . The P L G A polymers are 
amorphous whereas L - P L A are crystalline. Depending on their molecular 
weight they erode in weeks or months(5#). To investigate the effect of 
erosion velocity the polymers were chosen with a molecular weight of ei-
ther 100,000 or 3,000 Da. The release was studied by incubation of the 
microspheres in phosphate buffer pH 7.4 at 37°C. Due to the slow degra-
dation of the polymers it was sufficient to replace the buffer at least every 
5 days. The released protein was determined by using a microBCA protein 
assay. The results for the two types of polymers are shown in Figure 12a 
and b. The release rate was clearly affected by polymer composition with 
P L G A faster than from P L A at the same molecular weight. In both cases, 
Figure 12. In vitro release of tetanus toxoid from different types of 
polymer: 
a) • P L A (Mw 100,000); • P L G A (Mw 100,000) 
b) a P L A (Mw 3,000); a P L G A (Mw 3,000) 
(Reproduced with permission from ref. 56. Copyright 1993 
Butterworth-Heinemann Ltd.) 
the release from the low molecular weight polymers is faster. This result is 
due to the smaller size of microspheres prepared from these polymers 
since the organic polymer solution had a lower viscosity. Other reasons 
could be their faster degradation due to differences in molecular weight. 
A l l preparations release over a period of weeks, as was intended. With the 
exception of low molecular P L G A , there is no substantial burst effect as 
reported for other vaccine preparations (59). 
A general disadvantage of methods that use chemical reactions or 
physical interactions like chromatographic methods for the determination 
of protein concentrations is the lack of structural information. We, there-
fore, tested the in vivo response to the encapsulated tetanus toxoid by in-
jecting the microspheres subcutaneously into mice. The sera was assayed 
for the antitoxin units using the toxin neutralization test(60-67) as well as 
an E L I S A test. Figure 13a and b show the results for all microspheres as 
well as a control injection of fluid toxoid and aluminum adsorbed toxoid. 
The use of microspheres increases the immune response compared to the 
fluid toxoid. The use of aluminum adsorbed toxoid produces initially 
higher antitoxin titers which decrease, however, more rapidly compared to 
the encapsulated toxoid. The levels resulting from microsphere injection 
are considerably higher than the estimated minimum protective level 
which is about 0.01 AU/mL(62) . The antibodies determined by the 
neutralization test and the IgG antibodies reach their maximum at different 
times. This could be explained by the induction of progressive affinity 
maturation tetanus antibodies induced by prolonged exposure to low 
concentrations of tetanus toxoid. 
Protein Delivery from Poly(anhydride) Microspheres. A major 
problem associated with many dosage forms for drug release is the release 
of large amounts of the drug during initial stages of release known as the 
initial burst-effect. For microspheres, this burst effect tends to be en-
hanced since microspheres have a larger surface area to volume ratio than 
more sizable slabs. In addition, the change of biological activity of pro-
teins can occur during microsphere formulation because of their sensitivity 
to environmental alternation. Our goal in this study was to prepare 
poly(anhydride) microspheres which permitted the controlled release of 
biologically active proteins without any initial burst in release. We se-
lected two enzymes, trypsin (Mw24,000) and heparinase (Mw43,000) in 
addition to B S A (Mw 62,000) which has been used as a model protein. 
The measurement of enzymatic activity allowed us to investigate the ef-
fect of microsphere formulation on protein activity. 
We encapsulated proteins into poly(anhydride) microspheres with 
the solvent evaporation method by using a double emulsion (54). 
However, this technique comprises of a number of formulation processes 
which may affect protein activity: contact of aqueous protein solution with 
• Fluid toxoid 
H PLAMW 3,000 
9 PLAMW 100,000 
m PLGAMW 3,000 
• PLGA MW 100,000 
• Alum-adsorbed toxoid 
time [weeks] 
• Fluid toxoid 
B PLAMW3,000 
• PLAMW 100,000 
0 PLGAMW 3,000 
• PLGAMW 100,000 
• Alum-adsorbed toxoid 
4 8 13 
time [weeks] 
Figure 13. Results from the in vivo test of tetanus toxoid loaded mi-
crospheres: 
a) In vivo neutralizing antibody response (antitoxin units/ml serum), 
b) IgG antibody response by ELISA. 
(Reproduced with permission from ref. 56. Copyright 1993 
Butterworth-Heinemann Ltd.) 
the organic phase, vortex mixing, exposure to ultrasound and freeze dry-
ing. 
The activity loss of proteins was measured based on the specific activity 
of proteins at each stage of the process (63). Table III shows the effect of 
the formulation process on the enzymatic activity of trypsin. 
Table III. Activity loss of trypsin after each 
step of microsphere preparation 
Preparation step remaining activity (%) 
Trypsin solution 100 
vortex mixing 100 
sonication for 30s 59 
3 h solvent evaporation 56 
freeze drying 59 
The sonication process which was performed in presence of the organic 
solvent to prepare a primary emulsion, causes the main activity loss of 
protein, while freeze-drying did not have any addition effect. It is known 
that ultrasound has an effect on the biological properties of proteins in 
aqueous solution due to a number of factors such as temperature, mixing 
and cavitation(64). Table IV shows the effect of ultrasound exposure pe-
riod on the activity loss of proteins during microsphere preparation to-
gether with the additional effect of some protein stabilizers(65). 
Table IV. Activity loss of trypsin during microsphere prepare 
tion (66) 
Period of Type of Amount of remaining 
sonication [s] stabilizer stabilizer (% activity 
w/w) 
10 none - 80.5 
20 none - 67.3 
30 none - 58.9 
30 B S A 5 58.6 
30 B S A 10 58.1 
30 Glycine 4 58.7* 
30 Glycine 7.5 59.8* 
30 Glycine 8 56.6* 
30 Glycine 15 57.2* 
* Differences within the error margin of the test 
The extent of activity loss becomes smaller with a decrease in the expo-
sure period of sonication. In addition, the decreased period did not reduce 
the size of the primary emulsion. These findings demonstrated that the ob-
served activity loss results from the sonication probe and not from the in-
crease in the interfacial area between aqueous and organic phase. Little ef-
fect of the stabilizers used here on activity loss was observed, indicating 
the poor potential of these substances to protect the investigated proteins 
against ultrasound exposure. Trypsin and heparinase were encapsulated to 
study the enzymatic activity of proteins in poly(anhydride) microspheres. 
Figure 14 shows the comparison of the remaining activity between the 
proteins encapsulated in microspheres and the proteins in a soluble form 
after incubation in phosphate buffer pH 7.4 at 37°C. At different stages of 
the experiment, the remaining % activity of proteins in microspheres was 
assessed by determining the activity of protein that could be extracted 
from these systems (66) These results clearly indicate that encapsulation 
of proteins inside poly(anhydrides) may stabilize their activity for a short 
period of time (l-2days). 
Figure 15 shows release profiles of B S A from p(FAD-SA) 25:75 at 
various protein loadings. No initial burst is observed irrespective of the 
protein loading. The protein is released for up to three weeks at a near-
constant rate. 
The release rate of protein depends on the monomer composition of 
poly (anhydrides) used as can be seen from Figure 16. Release periods of 
several days to a couple of weeks are possible for poly(anhydride) micro-
spheres by changing their monomer composition(66). 
Biodegradable Injectable Nanospheres Composed of Diblock 
Poly(ethyleneglycol)-Poly(lactic-co-glycolic acid) Copolymers A major 
challenge in the area of parenteral administration of drugs is the develop-
ment of a drug carrier that is small enough for intravenous application and 
which has a long circulation half-life. There are numerous potential appli-
cations for such a system: the suppression of toxic side effects which can 
occur when the drug is injected in the form of a solution, or the protection 
of sensitive compounds against degradation in the plasma. Consequently 
there have been many approaches to develop such systems (67-68). The 
major obstacle in the use of injectable systems is the rapid clearance from 
the blood stream by the macrophages of the reticuloendothelial system 
(RES). Polystyrene particles as small as 60 nm in diameter, for example, 
are cleared from the blood within 2 to 3 min(69). By coating these parti-
cles with block copolymers based on polyethylene glycol and polypropy-
lene glycol, their half-life was significantly increased (70). Polystyrene 
particles are, however, not biodegradable and are not therapeutically use-
ful. For this reason, only liposome systems have been developed for intra-
venous administration (71-76). Due to their small size they were expected 
time [h] 
Figure 14. Stability of Heparinase and Trypsin with and without 
polymer encapsulation in phosphate buffer pH 7.4: o Heparinase 
solution, • Heparinase encapsulated, • Trypsin solution, • Trypsin 
encapsulated. 
(Reproduced with permission from ref. 66. Copyright 1993 Plenum 
Press.) 
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Figure 15. Release of B S A from poly (anhydride) microspheres de-
pending on loading: o 1% BSA, • 2% B S A , • 4% B S A . 
(Reproduced with permission from ref. 66. Copyright 1993 Plenum 
Press.) 
to freely circulate in the blood. It has been found, however, that they are 
cleared from the blood by uptake through the reticuloendothelial system 
(RES). The coating of liposomes with poly(ethyleneglycol) (PEG) in-
creased their half life substantially (71-77). The presence of the flexible 
and relatively hydrophilic PEG chains induces a steric effect at the lipo-
some's surface, thus reducing protein adsorption and RES uptake (77). 
Rather than using liposomes, we designed PEG-coated biodegrad-
able nanospheres that consist of polymer only(7&). These are among the 
first degradable polymer-based systems with potential use for prolonged 
intravenous administration or drug targeting. 
The 'ideal' nanosphere (Figure 17) is biodegradable, biocompatible, 
has a size of less than 200 nm, and has a rigid biodegradable core. The 
PEG-coated surface theoretically provides a prolonged half-life in the 
blood by masking it from the RES. We chose the F D A approved 
polyesters poly(lactic-co-glycolic acid) (PLGA) to form the core of the 
particles. These polymers allow us to adjust erosion rates and therefore 
drug release by changing the monomer ratio. We synthesized a series of 
diblock copolymers P L G A - P E G , starting with P E G of various chain 
lengths and progressively increased the chain length of P L G A . Stannous 
octoate was used as a catalyst for the ring-opening polymerization of lac-
tide and glycolide in the presence of monomethoxy polyethylene glycol 
( M P E G ; M w 5,000; 12,000 and 20,000). The polymers obtained were 
characterized by nuclear magnetic resonance spectroscopy (NMR) , gel 
permeation chromatography (GPC), infrared spectroscopy (IR), differen-
tial scanning calorimetry (DSC) and X-ray diffraction. The polymerization 
reaction was followed by GPC from which molecular weight and polydis-
persity were determined. The consumption of lactide and glycolide can be 
observed from a decrease of peak D (Figure 18). The shifting of the peak 
P towards lower retention times (higher molecular weights) indicates that 
an addition reaction takes place at the hydroxyl end group of the P E G 
chains. The polydispersity remains low during the polymerization 
(Mn/Mw less than 1.1). Both the crystallinity and the glass transition tem-
perature (Tg) were determined by using DSC. The diblock copolymers 
show a single Tg, which shifts to higher temperatures with an increase of 
the P L G A chain length inside the P L G A - P E G (Figure 19). A complete 
discussion of the DSC results can be found elsewhere(79). Random lactic 
acid-ethylene oxide copolymers show two distinct Tg's (80), suggesting a 
phase separation inside the polymer. We suppose that the single Tg we ob-
served is due to an entanglement effect of long P E G and P L G A chains in 
the polymers, which cannot easily phase-separate. The exact chemical 
composition of the polymers was determined by i 3 C N M R spectroscopy. 
Sterically stabilized particles were prepared from diblock P L G A -
P E G copolymers or from blends of P L G A and P L G A - P E G . These poly-
mers were dissolved in a common solvent (ethyl acetate or methylene 
120 
time [days] 
Figure 16. Release of B S A from poly(anhydride) microspheres de-
pending on polymer type: o p(SA), • p(FAD-SA) 8:92, • p (FAD-
SA) 25:75, • p(FAD-SA) 44:56. 
(Reproduced with permission from ref. 66. Copyright 1993 Plenum 
Press.) 
Figure 17. Schematic representation of an 'ideal' nanosphere having a 
biodegradable drug containing core and a coating of Polyethylene 
glycol chains. 
"i 1 1 1— 
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time (minutes) 
Figure 18. ATime course of the polymerization reaction between 
P E G and lactide/glycolide followed by GPC: Peak P: polymer P E G -
P L G A , peak D: starting material (glycolide+lactide). 
Figure 19. DSC thermograms of P L G A - P E G diblock copolymers 
(heating rate 10 °C/min, M W PEG=5000, for increasing chain length 
of P L G A ) . 
chloride). A n 0 / W emulsion was formed by vortex mixing and sonicating 
for one minute. The organic solvent was then slowly evaporated, at room 
temperature, under gentle stirring for two hours. Slow removal of the sol-
vent allows the reorganization of the polymer chains inside and on the sur-
face of the droplets. By optimizing the viscosity of the organic phase, the 
volume ratio of the two phases and the sonication parameters, nanospheres 
of a mean size of about 150 nm were obtained. After removal of the or-
ganic solvent, the nanospheres were isolated from the aqueous phase by 
centrifugation. They could later be readily redispersed in water, probably 
due to the presence of P E G chains on their surface. 
The nanospheres were characterized by various methods. The sur-
face composition of lyophilized particles was determined by X-ray photo-
electron spectroscopy (XPS). Figure 20 shows the carbon Is envelopes 
that were observed by analyzing the nanosphere powder. One main carbon 
environment is observed for PEG. It corresponds to the ether carbon C-O 
(81). The spectrum of P L G A polymer (curve a) shows three main carbon 
environments. In the case of P E G - P L G A nanospheres, the peaks are still 
present. As the information obtained by XPS corresponds to the first lay-
ers on the nanosphere's surface (about 5 nm(S2)), this spectrum indicates 
that P E G is present on the surface of the nanosphere powder. Moreover, 
we verified that P E G remains on the surface after incubation in distilled 
water for 24 hours at 37 °C. 
To investigate the in vivo half life of the systems, the nanospheres 
were labeled with 1 ^Indium, which has been used for gamma-scintigra-
phy studies in humans (83). llHn was attached directly to the polymer 
chain by complex formation following a method that has already been 
used for liposomes (83). The incubation at 37 ° C in PBS or horse serum 
for more than 24 hours showed that there was less than 4 % label loss. 
This indicated that the label is bound tightly enough to prevent loss during 
in vivo study. Subsequently biodistribution studies were performed by in-
jecting 1 1 1 In-labeled P L G A and PEG-coated nanospheres into the tail vein 
of Balb/c mice (18-20g). Five minutes after injection of uncoated P L G A 
nanospheres, 40% of nanosphere-associated U 1 l n radioactivity was found 
in the liver and approximately 15% in the blood. In the case of P E G -
coated nanospheres, the results were reversed (15% of injected radioactiv-
ity in the liver, 60% in the blood). After four hours, 30% of the 
nanospheres were still circulating in the blood, whereas the P L G A 
nanospheres had disappeared completely from the blood. 
These results are very encouraging and we hope that these 
nanospheres might be used as drug carriers for intravenous administration 
in the future. Studies are now underway to achieve the encapsulation of 
different hydrophobic drugs and small peptides into the core of these 
nanospheres. We are also determining the effect of P E G molecular weight 
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Figure 20. Surface analysis by X P S of P L G A powder: a) P L G A 
powder, b) P E G crystals, c) P L G A - P E G nanospheres. 
and density on the RES uptake and on drug encapsulation efficiency and 
release. 
Summary 
Progress in various fields of protein delivery has been illustrated. Using 
poly(anhydrides) as a model we showed that it is possible to describe 
erosion mechanisms and to develop mathematical models of the complex 
processes involved in polymer degradation. Based on such models the de-
sign of delivery systems using computers might become possible in the 
future. Concerning manufacturing technologies for protein delivery, we 
showed how existing systems, like microspheres, can be improved and 
provided the development of vaccines as an example for future application 
of such systems. Finally the recent progress in the development of new 
dosage forms was illustrated with the example of biodegradable 
nanospheres with an increased circulation half-life. A l l these projects aim 
at a better understanding and an improved design of protein delivery sys-
tems. 
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